New York Just Recorded Its Lowest Overdose Death Toll Since Before COVID. Here's What Changed.

The number that tells the story is simple: 4,567.

That's how many New Yorkers died of a drug overdose in 2024, according to preliminary CDC data cited by Governor Kathy Hochul. Compare it to 6,688 deaths in 2023, and the scale of the shift becomes apparent — a 32 percent decline, the largest single-year drop the state has recorded, and the lowest death toll since before the COVID-19 pandemic upended everything.

Then OASAS Commissioner Dr. Chinazo Cunningham reported in late December 2025 that the decline continued into a second consecutive year — overdose deaths fell by more than 30 percent again in 2025. That's two years of sustained, measurable progress in a crisis that spent the better part of a decade trending in the wrong direction.

Something changed. And the question worth asking now is what, exactly — because the answer determines whether New York has genuinely turned a corner or is managing a temporary reprieve.

---

The Scale of the Crisis It Replaced

Context matters here. Before celebrating the numbers, it's worth remembering where they came from.

New York's overdose epidemic intensified sharply as fentanyl replaced heroin in the illicit drug supply around 2016. By 2017, the state was recording roughly 3,000 overdose deaths annually. That number climbed steadily through the pandemic years, peaking at over 6,500 in 2023. About 77 percent of those deaths involved opioids — primarily fentanyl and its analogs, drugs so potent that a misjudged dose measured in micrograms can be lethal.

For families and communities, the numbers mask something harder to quantify: the accumulation of loss. Ten years of rising overdose deaths meant that by 2023, nearly every extended family in the state had either experienced a loss directly or knew someone who had.

The 2024 and 2025 declines don't undo that history. But they do represent roughly 4,000 people who are alive who might not have been under the trajectory of even two years ago.

---

What Actually Drove the Numbers Down

State officials credit a combination of investments that compounded over several years — none of them a single magic intervention, but rather an accumulation of programs that reached different populations through different channels.

The most straightforward contributor was naloxone. New York has flooded the state with the overdose-reversing medication at a scale few states have matched. Through an online ordering portal launched by OASAS, New Yorkers can request fentanyl test strips, xylazine test strips, and naloxone kits for free — no prescription required, delivered by mail. As of mid-2025, more than 13.2 million fentanyl test strips and 10 million xylazine test strips had been ordered through that portal alone. The state Department of Health distributed an additional 537,600 naloxone kits through its 1,300-plus registered overdose prevention programs between January 2024 and April 2025.

The reach of those programs matters as much as the supply. Those 1,300 programs operate across more than 5,000 sites statewide, providing training and free naloxone to anyone who wants it. The logic is straightforward: more naloxone in more hands means more overdoses interrupted before they become deaths.

Medication-assisted treatment also expanded significantly. OASAS has funded 11 Mobile Medication Units — essentially health clinics on wheels — that bring buprenorphine and other addiction medications directly to underserved communities. Rural upstate counties, areas with limited public transit, communities where the nearest treatment provider is an hour's drive away: these are places where the mobile units fill a gap that brick-and-mortar programs couldn't close. The state's FY2026 budget includes funding to add more.

The MATTERS network — a statewide rapid referral system that connects people in emergency departments, correctional facilities, and community clinics to outpatient opioid treatment — contributed by tightening the window between crisis contact and enrollment in care. When someone arrives at an emergency room after an overdose, MATTERS gives providers a pathway to link that person to ongoing buprenorphine treatment within hours rather than weeks.

Underlying all of it is money. New York has made nearly $400 million in opioid settlement funds available — more than any other state in the country — channeled through the Opioid Settlement Fund Advisory Board into prevention, treatment, harm reduction, and workforce development.

---

The Gap the Numbers Don't Show

The decline in overdose deaths is real. It is also, by the state's own acknowledgment, unevenly distributed.

State Senator Nathalia Fernandez, reacting to the 2024 data, put it plainly: "Until the data is disaggregated by race, it is unclear whether this decline is reaching all communities equally, especially Black and Brown New Yorkers." The Alliance for Rights and Recovery has echoed that concern, noting that while statewide overdose deaths fell, the decline was not proportional across racial and ethnic groups.

Historically, the opioid epidemic's deadliest phases hit white, rural communities hardest — and early investments in naloxone distribution and treatment access were concentrated there. As fentanyl became more widespread across demographics, communities of color began bearing a larger share of overdose deaths, even as those communities were less likely to access buprenorphine or other medications through formal treatment programs.

Whether the programs credited with the 2024-2025 decline closed that gap or left it intact is a question that state data hasn't fully answered. More granular reporting on who is reaching treatment, who is receiving naloxone, and whose death counts are improving is something advocates have pressed OASAS to prioritize in 2026.

---

What Threatens the Progress

New York's declines came against a backdrop of serious federal turbulence. In January 2026, the Trump administration sent letters terminating hundreds of SAMHSA grants supporting mental health and substance use programs — cuts that could have totaled as much as $2 billion. The administration reversed course shortly afterward, but the episode illustrated how fragile federally funded programs can be.

For New York specifically, state-funded programs and opioid settlement money provide a buffer that many other states lack. But that buffer isn't unlimited, and it doesn't cover everything. Programs that rely on federal pass-through funding — particularly harm reduction services and peer support programs — are more exposed to federal policy shifts.

OASAS Commissioner Cunningham's December 2025 report mentioned workforce investment as a key priority, and that's telling. Treatment capacity is ultimately constrained by the number of trained providers, and that number has not kept pace with need. Mobile units and referral networks can only connect people to treatment that actually exists.

---

What Comes Next

For New Yorkers in active addiction or families trying to find help, the practical landscape in 2026 looks meaningfully better than it did three years ago — more naloxone, more mobile options, faster pathways to buprenorphine, more places to call or text when someone is in crisis.

The HOPEline at 1-877-8-HOPENY (1-877-846-7369) operates 24 hours a day, seven days a week. Treatment options — including detox, inpatient, residential, and outpatient care — are searchable through the OASAS treatment finder. And the same online portal that has distributed millions of test strips remains open for any resident to order free harm reduction supplies.

Whether those gains hold through 2026 depends on whether New York can sustain its own investments while the federal picture remains unsettled. Two consecutive years of 30-plus percent declines is a remarkable result. Keeping that trend intact will require the same sustained pressure — not just on death counts, but on the conditions that drive them.